Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Wonder

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The New Zealand Medical Journal|December 7, 2011
Access to new medicines in New Zealand compared to AustraliaMichael Wonder, Richard Milne
The New Zealand Medical Journal|January 13, 2012
Response to PHARMAC on Access to new medicines in New Zealand compared to AustraliaRichard Milne, Michael Wonder
The New Zealand Medical Journal|August 19, 2016
Subsidised access to new melanoma drugs: in need of further innovation?Michael Wonder, Rosalie Fisher
Australian Health Review : a Publication of the Australian Hospital Association|August 10, 2015
Author reply: exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New ZealandColman B Taylor, Michael Wonder
Seminars in Oncology|March 28, 2018
"Mind the Gap" RevisitedJohn R Zalcberg, Michael Wonder
Australian Health Review : a Publication of the Australian Hospital Association|May 11, 2019
Analysis of sponsor hearings on health technology assessment decision makingMelinda Flowers, Sean Lybrand, Michael Wonder
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 18, 2013
Early scientific advice obtained simultaneously from regulators and payers: findings from a pilot study in AustraliaMichael Wonder, Martin E Backhouse, Edward Hornby
Pharmacoeconomics|June 17, 2003
Rescuing patients from the rule of efficiency: a need to debate the 'rule of rescue'Sophia Kessabi, Richard de Abreu Lourenco, Michael Wonder
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2012
Australian managed entry scheme: a new manageable process for the reimbursement of new medicines?Michael Wonder, Martin E Backhouse, Sean D Sullivan
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2011
Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot studyMartin E Backhouse, Michael Wonder, Edward Hornby, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The New Zealand Medical Journal|December 7, 2011
Access to new medicines in New Zealand compared to AustraliaMichael Wonder, Richard Milne
The New Zealand Medical Journal|January 13, 2012
Response to PHARMAC on Access to new medicines in New Zealand compared to AustraliaRichard Milne, Michael Wonder
The New Zealand Medical Journal|August 19, 2016
Subsidised access to new melanoma drugs: in need of further innovation?Michael Wonder, Rosalie Fisher
Australian Health Review : a Publication of the Australian Hospital Association|August 10, 2015
Author reply: exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New ZealandColman B Taylor, Michael Wonder
Seminars in Oncology|March 28, 2018
"Mind the Gap" RevisitedJohn R Zalcberg, Michael Wonder
Australian Health Review : a Publication of the Australian Hospital Association|May 11, 2019
Analysis of sponsor hearings on health technology assessment decision makingMelinda Flowers, Sean Lybrand, Michael Wonder
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 18, 2013
Early scientific advice obtained simultaneously from regulators and payers: findings from a pilot study in AustraliaMichael Wonder, Martin E Backhouse, Edward Hornby
Pharmacoeconomics|June 17, 2003
Rescuing patients from the rule of efficiency: a need to debate the 'rule of rescue'Sophia Kessabi, Richard de Abreu Lourenco, Michael Wonder
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2012
Australian managed entry scheme: a new manageable process for the reimbursement of new medicines?Michael Wonder, Martin E Backhouse, Sean D Sullivan
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2011
Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot studyMartin E Backhouse, Michael Wonder, Edward Hornby, et al.
Pageof 3